NPCE shareholders absorbed a 37% loss after the Company disclosed a third-quarter revenue miss and a cut of about $9 million to 2026 revenue guidance. An investigation into potential securities law violations is focused on the losses investors took in the selloff. NPCE shareholders absorbed a 37% loss after the Company disclosed a third-quarter revenue miss and a cut of about $9 million to 2026 revenue guidance. An investigation into potential securities law violations is focused on the losses investors took in the selloff.
NEW YORK--(BUSINESS WIRE)---- $NPCE #ClassActionLawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired NeuroPace securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com,.
NeuroPace's discounted valuation and RNS growth potential appeal, but weak implant activity, execution challenges and regulatory risks cloud the outlook.
NeuroPace raised its 2026 revenue outlook on August 11, 2026, then cut it to $91-$92 million one quarter later. The investigation concerns potential federal securities law violations tied to those statements.
NeuroPace NASDAQ: NPCE cut its full-year revenue outlook after third-quarter sales fell short of management's expectations, as disruptions at major treatment centers and changes to its sales organization slowed procedures using its RNS System.
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.11 per share a year ago.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. Third Quarter 2026 Financial Highlights Total revenue of $23.1 million in the third quarter of 2026 RNS System revenue of $22.9 million in the quarter, representing 1.4% growth compared to the third quarter of 2025 Net los.
NeuroPace (NASDAQ: NPCE - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings. Insider and Institutional Ownership 78.8% of NeuroPace shares are